Gonadorelin Hydrochloride

Gonadorelin Hydrochloride is a synthetic peptide corresponding to a hypothalamic hormone also known as LHRH or GnRH. As a single dose it stimulates the release of LH and FSH from the anterior pituitary, whereas continuous administration results in downregulation of LH and FSH levels followed by suppression of ovarian and testicular steroid biosynthesis.

Online Inquiry

Specification Technical Data Related Products Customer reviews and Q&A Useful Tools Publications

CAT#	10-101-86
CAS	33515-09-2 (net), 51952-41-1 (hydrochloride)
Background	Gonadorelin Hydrochloride is the chloride form of a hypothalamic peptide that stimulates the release of follicle stimulating hormone and luteinising hormone from the pituitary gland. It contains not less than 88.0% and not more than 98.0% of the peptide C55H75N17O13, calculated with reference to the anhydrous substance. It is obtained by synthesis.
Synonyms/Alias	Gonadotropin-releasing hormone; Luteinizing hormone-releasing factor; Fertagyl; Gonadoliberin; Hypocrine; Lutrefact; Relefact; Gonadorelin hydrochloride; Gonadorelin HCl; Factrel; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide hydrochloride; L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-glycyl-L-leucyl-L-arginyl-L-prolyl-glycinamide hydrochloride
Chemical Name	(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-5-oxopyrrolidine-2-carboxamide;hydrochloride
M.F/Formula	C55H75N17O13
M.W/Mr.	1218.76
Sequence	One Letter Code: XHWSYGLRPG Three Letter Code: H-Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2.HCl
Labeling Target	Gonadotropin-releasing hormone (GNRH) Receptor
Application	Gonadorelin hydrochloride stimulates anterior pituitary to release the gonadotropin LH.
Activity	Agonist
Areas of Interest	Pituitary & Hypothalamic Hormones Veterinary Medicine
Target	Gonadotropin-releasing hormone receptor

CAT#	Product Name	M.W	Molecular Formula	Inquiry
10-101-21	Histrelin Acetate	1383.6	C66H86N18O12	Inquiry
10-101-22	Leuprolide Acetate	1269.46	C59H84N16O12.C2H4O2	Inquiry
10-101-23	Lysipressin	1056.2	C46H65N13O12S2	Inquiry
10-101-66	Kassinin	1334.54	C59H95N15O18S	Inquiry
10-101-87	GRF (human) Acetate	5039.72	C215H358N72O66S	Inquiry

If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.

Source#	Synthetic
Length	10
Long-term Storage Conditions	−20°C
InChI	InChI=1S/C55H75N17O13.ClH/c1-29(2)19-38(49(80)67-37(9-5-17-60-55(57)58)54(85)72-18-6-10-43(72)53(84)62-25-44(56)75)66-46(77)26-63-47(78)39(20-30-11-13-33(74)14-12-30)68-52(83)42(27-73)71-50(81)40(21-31-23-61-35-8-4-3-7-34(31)35)69-51(82)41(22-32-24-59-28-64-32)70-48(79)36-15-16-45(76)65-36;/h3-4,7-8,11-14,23-24,28-29,36-43,61,73-74H,5-6,9-10,15-22,25-27H2,1-2H3,(H2,56,75)(H,59,64)(H,62,84)(H,63,78)(H,65,76)(H,66,77)(H,67,80)(H,68,83)(H,69,82)(H,70,79)(H,71,81)(H4,57,58,60);1H/t36-,37-,38-,39-,40-,41-,42-,43-;/m0./s1
InChI Key	UPRWQSQENCASAD-HBBGHHHDSA-N
Canonical SMILES	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6.Cl
Isomeric SMILES	CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)NC(=O)CNC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)NC(=O)[C@H](CC5=CN=CN5)NC(=O)[C@@H]6CCC(=O)N6.Cl
BoilingPoint	N/A
References	Recently a patient with severe hypogonadotropic hypogonadism who was given luteinizing hormone-releasing hormone (Factrel) through an infusion pump developed a wheat-and-flare reaction at the sites of injection. Treatment with luteinizing hormone-releasing hormone was discontinued and the immune response was characterized. Skin testing by skin prick test was positive for luteinizing hormone-releasing hormone but negative for vehicle. Radioallergosorbent testing was performed with allergic (patient serum with an elevated serum immunoglobulin E concentration and allergic to inhalant allergens including ragweed pollen) and nonallergic controls. Radioallergosorbent testing was negative for luteinizing hormone-releasing hormone-reactive immunoglobulin E antibodies. Radioimmunoassay of serum of the allergic patient antibody to luteinizing hormone-releasing hormone was positive only for immunoglobulin E. Maximum binding occurred at a dilution of 1:10. Sera from nonallergic and unchallenged patients were negative. It is concluded that this patient developed hypersensitivity reactions caused by IgE antibody to luteinizing hormone-releasing hormone. Foster, W. G., Jarrell, J. F., Dolovich, J., & YoungLai, E. V. (1989). Immunoglobulin-mediated hypersensitivity in response to long-term treatment with gonadorelin hydrochloride (Factrel) in a female patient. American journal of obstetrics and gynecology, 160(4), 979-983.
Melting Point	N/A